TY - JOUR T1 - Increased Plasma Caveolin-1 Levels Are Associated with Progression of Prostate Cancer among Japanese Men JF - Anticancer Research JO - Anticancer Res SP - 1893 LP - 1897 VL - 33 IS - 5 AU - SATORU SUGIE AU - SHOICHIRO MUKAI AU - HIROMASA TSUKINO AU - YOSHINOBU TODA AU - TAKENORI YAMAUCHI AU - ICHIRO NISHIKATA AU - YOSHIKI KURODA AU - KAZUHIRO MORISHITA AU - TOSHIYUKI KAMOTO Y1 - 2013/05/01 UR - http://ar.iiarjournals.org/content/33/5/1893.abstract N2 - Aim: Up-regulation of caveolin-1 (CAV1) is associated with aggressive prostate cancer. Among Caucasian and African-American patients, plasma CAV1 levels are elevated in patients with castration-resistant prostate cancer (CRPC), but not in those with hormone-sensitive prostate cancer (non-CRPC), which implies that CAV1 could be a therapeutic target for CRPC. Here, we evaluated associations between plasma CAV1 levels and these types of cancer in Japanese men, and CAV1 expression in PC3 (CRPC) and LNCaP (non-CRPC) cell lines. Materials and Methods: Plasma samples were obtained from 58 patients with prostate cancer: 36 with CRPC and 22 with non-CRPC. Enzyme-linked immuno sorbent assay (ELISA) kits were used to determine CAV1 plasma levels; qRT-PCR and western blots were used to evaluate the expression of CAV1 mRNA and protein in cell lines. Results: Plasma CAV1 levels in patients with CRPC were greatly higher than in those with non-CRPC (1.46±1.37 ng/ml in CRPC; 0.56±0.32 ng/ml in non-CRPC, p<0.004). Western blot and real-time qRT-PCR showed CAV1 protein and mRNA in PC3 cells to be significantly overexpressed compared to its expression in LNCaP cells (p<0.0001). Conclusion: Our results showed a relationship between CAV1 expression and prostate cancer progression, and support the possibility of CAV1 as a therapeutic target for CRPC. ER -